Clinical Trials from The University of Texas Health Science Center at Houston

Studies available for: Heart Attack

See a study that interests you? Contact that study's coordinator for more information on how to participate.

Study Information:

Study Title:TRACER- Thrombin Receptor Antagonist for Clinical Event Reduction in ACS

Study Location:Houston, TX

Facility Name:Memorial hermann Heart and Vascular Institue, TMC

Study Description:A multi-center randomized, double blind, placebo-controlled, phase 3 study to evaluate safety and efficacy. The TRA-CER study in Acute Coronary Syndrome is designed to address the effects of SCH 530348, an investigational compound which inhibit the most potent stimulus of platelet activation, thrombin, which is a driver of the clotting process. The primary objective is to evaluate the hypothesis that SCH 530348 added to standard of care will reduce the incidence of atherothrombotic ischemic events relative to standard of care alone, as measured by the composite of cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization. The Phase III TRACER Acute Coronary Syndrome trial will use an oral 40 mg loading dose and a daily 2.5 mg maintenance dose until the study is completed. Patients will be randomized to either placebo plus standard medical care (including aspirin and clopidogrel) or to TRA once daily

HSC Number:HSC-MS-08-0049

Funding Agency/Source:Schering Plough Research Institute (SPRI)

Subject Information:

Subject Age Range:18 yrs or older

Inclusion/Exclusion Criteria:The study population will comprise of moderate to high risk NSTEACS Patients. Age range: 18 yrs or older and may be of either sex and of any race. History of cardiac ischemia related symptoms of atleast 10 minutes duration ¡Ü 24 hours prior to hospital presentation. Concurrent biomarker evidence - elevated troponin I or troponin T greater than the stated upper limit of normal at the study site, or creatinine kinase-myocardial band greater than the upper limit of normal at the study site. And or concurrent electrocardiogram changes ¨C comprising new or presumably new ST-segment depression, or transient ST segment elevation in at least two contiguous leads.

Study Coordinator(s) Information:

Name:Truc baccam

E-mail:Truc.Baccam@uth.tmc.edu

Phone Number:713-500-5214

Principal Investigator Information:

Name:H. Vernon Anderson

Study Information:

Study Title:CRISP: Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction—CRISP AMI

Study Location:Houston, TX

Facility Name:Memorial Hermann heart and Vascular Institute, TMC

Study Description:This protocol is a multi-center, randomized, controlled study in subjects with anterior acute ST-segment–elevation myocardial infarction (STEMI), to evaluate whether counterpulsation by intra-aortic balloon (IAB), placed before mechanical reperfusion, will result in decreased infarct size. As a secondary objective, major adverse cardiac events (MACE), defined as death, reinfarction, and congestive heart failure (CHF), will be assessed to 6 months postprocedure. The study devices and therapy being studied have been cleared by the U.S. Food and Drug Administration (FDA) and in use for over 20 years. The study will be conducted at 30 clinical sites in the United States, Europe, Australia, and New Zealand and will include 300 subjects with anterior acute STEMI, defined as greater than or equal to 2 mm in 2 contiguous anterior leads or greater than or equal to 4 mm total in anterior leads, confirmed by electrocardiogram (ECG).

HSC Number:HSC-MS-09-0033

Funding Agency/Source:Datascope Corp.

Subject Information:

Subject Age Range:>18yrs.

Inclusion/Exclusion Criteria:Subjects with anterior acute ST-segment–elevation myocardial infarction (STEMI), defined as greater than or equal to 2 mm in 2 contiguous anterior leads or greater than or equal to 4 mm total in anterior leads, confirmed by electrocardiogram (ECG )

Study Coordinator(s) Information:

Name:Mary Vooletich, RN

E-mail:Mary.Vooletich@uth.tmc.edu

Phone Number:713-500-6550

Principal Investigator Information:

Name:Dr. Richard Smalling, MD. Ph.D

Study Information:

Study Title:ALERTS: AngeLmed for Early Recognition and Treatment of STEMI

Study Location:Houston, TX

Facility Name:Memorial Hermann Heart and Vascular Institue, TMC

Study Description:This is a randomized, prospective clinical investigation with blinded CORE laboratories, and an independent clinical events adjudication committee that will evaluate the effectiveness of the AngelMed Guardian System as compared with the standard of care in reducing the incidence of the composite of death, new Q-wave MI and presentation > 2 hours for thrombotic coronary occlusion events among subjects at a high-risk of recurrent myocardial infarction. The ALERTS Study will enroll up to 3000 consecutive subjects who have been identified as having a high risk of a MI due to ACS or bypass surgery. The subjects will be implanted with the Guardian System and will be randomized 1:1 to alerting and no alerting after implantation. Half of the subjects will be randomly assigned to the treatment group using the Guardian System with an EXD and alerting turned on and the other half assigned to the control group with the Guardian System alerting turned off, no EXD provided. Patients will know if the

HSC Number:HSC-MS-09-0042

Funding Agency/Source:Angel Medical Systems

Subject Information:

Subject Age Range:atleast 21 yrs of age.

Inclusion/Exclusion Criteria:The study population includes subjects presenting with high-risk acute coronary syndromes or multi-vessel coronary artery bypass surgery as a result of coronary artery disease Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following: a) Post-menopause or amenorrheic during the past year b) Surgical sterilization c) Use of effective contraceptive method

Study Coordinator(s) Information:

Name:Mary Vooletich, RN

E-mail:Mary.Vooletich@uth.tmc.edu

Phone Number:713-500-6550

Principal Investigator Information:

Name:Dr. RIchard Smalling, MD, Ph.D

Study Information:

Study Title:PATCAR: Pre-Hospital Administration of Lytic with Urgent Culprit Artery Revascularization

Study Location:Houston, TX

Facility Name:Memorial Hermann Hospital, Heart and Vascular Institue, TMC

Study Description:Acute myocardial infarction (MI) continues to be the leading cause of death in the US. Neither intravenous (IV) reduced dose fibrinolysis nor primary coronary stenting has proven to be an ideal therapeutic regimen. The combination of techniques including pre-hospital reduced dose fibrinolysis followed by emergency cardiac catheterization may be an optimal therapeutic regimen for patients with ST elevation myocardial infarction (STEMI). Preliminary results by our group and colleagues from four other high volume centers suggest that the 30-day mortality in acute MI could be reduced from 6-10% to less than 4% with a coordinated system of care similar to that practiced for trauma patients across the country today. No large scale experience in this country or Europe with pre-hospital reduced dose fibrinolysis followed by emergency coronary angiography, and stenting has been reported to date. A coordinated strategy for treatment of all Acute MI patients in the US should significantly re

HSC Number:HSC-MS-03-021

Funding Agency/Source:NA

Subject Information:

Subject Age Range:18 yrs. and older

Inclusion/Exclusion Criteria:Study population: 1) Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes 2) ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads. 3) Less than 6 hr after onset of sustained chest pain. 4) Age 18 years or older

Study Coordinator(s) Information:

Name:Mary Vooletich, RN

E-mail:Mary.Vooletich@uth.tmc.edu

Phone Number:713-500-6550

Principal Investigator Information:

Name:Dr. Richard Smalling, MD, Ph.D

CV:Information on the Principal Investigator

Study Information:

Study Title:Century Health Study

Study Location:Houston, Tx

Facility Name:University of Texas Medical School

Study Description:The Century Health Study is a collaboration between UT Medical School and Memorial Hermann Hospital looking at advanced treatment for patients with documented heart disease and those who have multiple risk factors for heart disease. It is a randomized 5 year study testing two strategies for treating heart disease. One study group will be scheduled for dietary and lifestyle assessments once a year throughout the study, the other group will be scheduled for dietary and lifestyle counseling 5 times during the first year and twice a year thereafter. Patients who are referred for a nuclear stress test may qualify for the study. All patients will undergo a cardiac PET scan at the first visit, at 2 and 5 years and basic chemistry and cholesterol levels will be drawn. At every visit, study participants will see a study nurse, cardiologist, and a dietician. The visits, testing, counseling, and lab work are provided at no cost to the participant. This program is meant to support and not to subs

More Information:website

HSC Number:HSC-MS-08-0312

Funding Agency/Source:Weatherhead Foundation

Subject Information:

Subject Age Range:40 years of age and above

Inclusion/Exclusion Criteria:Inclusion criteria: Multiple cardiovascular risk factors such as current or recent smoking, diabetes, high cholesterol, high blood pressure, positive family history of heart disease less than 60 years of age; body mass index of 35 or less; calcium score of >400; History of coronary artery bypass surgery; coronary angioplasty and/or stent procedure; documented heart disease; chest pain symptoms. No history of liver disease or kidney disease

Study Coordinator(s) Information:

Name:Catey Carter, RN

E-mail:catharine.v.carter@uth.tmc.edu

Phone Number:713-500-5200

E-mail:ms.century@uth.tmc.edu

Phone Number:713-500-5200

Principal Investigator Information:

Name:Stefano Sdringola, MD